ICD 2025: New data demonstrate Nemluvio®'s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years

Article content
Sorry, your browser doesn't support embedded videos.
Article content
An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years 1
Results build on data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one assessing long-term safety and efficacy in prurigo nodularis 1-3
This follows the presentation of data from the ARCADIA long-term extension study at the Revolutionizing Atopic Dermatitis (RAD) Conference earlier this month, which showed Nemluvio is well tolerated with sustained and increased improvements in efficacy outcomes in atopic dermatitis patients up to two years 4
Article content
Article content
ZUG, Switzerland — Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data show Nemluvio is well tolerated and associated with sustained and clinically meaningful improvements in symptoms including itch and skin lesions, during prolonged treatment up to two years. 1 These new data will be presented as a late-breaking session at ICD, on Saturday, June 21, 2025 at 08:30 AM CET.
Article content
is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules, which have a substantial impact on patients' quality of life.
Article content
5-7
Article content
Nemluvio
Article content
Article content
is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31.
Article content
8,9,10
Article content
IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation, skin barrier dysfunction, and fibrosis in prurigo nodularis.
Article content
8-11
Article content
It is also the first and only biologic approved for prurigo nodularis as well as atopic dermatitis with four-week dosing intervals from the start of treatment.
Article content
9,10
Article content
The OLYMPIA long-term extension study was designed to assess the safety and efficacy of Nemluvio in patients with prurigo nodularis up to four years and includes 508 patients from the phase II trial or the phase III OLYMPIA 1 and 2 trials. 1 Results show that treatment with Nemluvio is associated with sustained and clinically meaningful improvements in symptoms of prurigo nodularis during prolonged treatment up to two years. 1 At Week 100 in evaluable patients, the interim analysis shows that:
Article content
More than 90% and 70% achieved at least a four-point improvement in itch, and being itch free or nearly itch free respectively, as measured by the Peak-Pruritus Numerical Rating Scale 1
At least 80% achieved 76‑100% healed pruriginous lesions 1
Approximately 75% reached clearance or almost-clearance of skin nodules when assessed using the Investigator's Global Assessment score 1
Article content
Nemluvio was well tolerated in the long-term treatment of prurigo nodularis and no new safety signals were identified in this study to date. 1
'These impressive results give us even more confidence in the value of nemolizumab – a much-needed innovative medicine that has the potential to deeply impact the prurigo nodularis treatment landscape. With this new treatment now approved in multiple markets including the EU and U.S., I'm thrilled to be able to see its meaningful impact in the real world.'
This follows presentation of results from the ARCADIA long-term extension study at the RAD Conference earlier this month, which showed that treatment with Nemluvio was well tolerated and associated with sustained and increased improvements in symptoms of atopic dermatitis during prolonged treatment up to two years. 4 Nemluvio was first approved in August 2024 by the United States Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis. 9 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. 9 To date, Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including the European Commission. Additional reviews and submissions are ongoing.
Article content
Galderma will also host a symposium at ICD, exploring the latest advances in addressing itch in both prurigo nodularis and atopic dermatitis. Separately, the company will share new data from across its Therapeutic Dermatology portfolio in acne, non-melanoma skin cancer, and rosacea.
Article content
More details on Galderma's scientific presentations at ICD can be found here.
Article content
Nemluvio
Article content
Article content
was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga
Article content
®
Article content
and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients.
Article content
12,13
Article content
About prurigo nodularis
Article content
Prurigo nodularis
Article content
is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas.
Article content
5-7
Article content
It is an underrecognized and underdiagnosed skin condition, and there are limited studies investigating its prevalence.
Article content
11,14,15
Article content
About Galderma
Article content
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information:
Article content
Ständer S, et a. Nemolizumab long-term efficacy and safety up to 100 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: An interim analysis. Presented at International Congress of Dermatology; June 18-21, 2025; Rome, Italy.
ClinicalTrials.Gov. A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501679). Available online. Accessed May 2025
ClinicalTrials.Gov. Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501666). Available online. Accessed May 2025
Silverberg, JI, et al. Nemolizumab long-term safety and efficacy up to 104 weeks in the ARCADIA open-label extension study in adolescents and adults with moderate-to-severe atopic dermatitis. Presented at Revolutionizing Atopic Dermatitis Conference 2025; June 6-7; Nashville, United States.
Huang AH, et al. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-1565. doi: 10.1016/j.jaad.2020.04.183
Pereira MP, et al. European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059-1065. doi: 10.1111/jdv.14570
Ständer S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42. doi: 10.1097/itx.0000000000000042
Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-182. doi: 10.1016/j.jaci.2019.08.013
Nemluvio U.S. Prescribing Information. Available online. Accessed May 2025
Nemluvio European Medicines Agency. Summary of Product Characteristics. Available online. Accessed May 2025
Bewley A, et al. Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments. Dermatol Ther (Heidelb). 2022;12(9):2039–2048. doi: 10.1007/s13555-022-00782-2
Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed May 2025
Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed May 2025
Ständer S, et al. Prevalence of prurigo nodularis in the United States of America: a retrospective database analysis. JAAD Int. 2020;2:28-30. doi: 10.1016/j.jdin.2020.10.009
Huang AH, et al. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol. 2020;140(2):480-483.e4. doi: 10.1016/j.jid.2019.07.697
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
For further information:
Article content
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Article content
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Article content
Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87
Article content
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Article content
Article content
Article content

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

National Post

2 days ago

• National Post

What we know about yawning, from why we do it to why it's contagious

Yawning is strange. Article content It's not obviously just mechanical, like a burp to release gas pressure, or just psychological, like a yelp to express fear or excitement. A yawn is more like a sneeze or a hiccup, an involuntary breath event that is sometimes more or less resistible. Article content Article content But what is really strange, almost unique among human behaviours, is that yawning is contagious. Article content New research on chimpanzees by a British team of cognitive scientists shows contagious yawning is not only common in other species, and can happen between species, but that it can also be induced in chimps by an obviously artificial humanoid robot, an android 'agent' that is just a creepy looking disembodied head and shoulders, and which doesn't even breathe, but which can still give a believable facsimile of a yawn. Article content Article content The paper, published this month in Nature Scientific Reports, details an experiment in which the chimps were shown three behaviours by the android: a full wide-mouth yawn, a more moderate gaping mouth, and a closed mouth. Article content 'The results showed that adult chimpanzees exhibited across-agent yawn contagion, with a graded response: the highest contagion occurred when the android displayed a fully wide-open mouth (Yawn condition), a reduced response when the mouth was partially opened (Gape condition), and no contagion when the android's mouth was closed,' the paper says. Article content Article content And the chimps did not only yawn in response to the yawning robot. They also 'engaged in behaviours associated with drowsiness,' basically by preparing a comfortable place to lie down. Article content Article content 'This suggests that yawning by an unfamiliar model may act as a contextual cue for rest, rather than merely triggering a motor resonance response,' the paper says. Article content Diverse species exhibit contagious yawning, certainly mammals like dogs and cats, but even fish, whose respiratory system shares evolutionary origins with our own. Article content Most vertebrates yawn, but those that are known to yawn contagiously are usually pack animals, somehow social. This suggests the evolutionary purpose of the yawn is at least partly at the level of the group, not just the individual. A sneeze just tries to blast stuff out of your nose, a burp just lets gas out of your belly, but a yawn means something to other people. Article content Not always, of course, Yawning might, for example, help cool the brain for optimal performance, as one theory holds. But yawning also involves empathy, as its contagious aspect shows. It is a social phenomenon, and catching, like laughter. Article content 'What I find strange is that if we see someone walking, we don't an feel urge to walk. But with yawning, we do,' said Ramiro Joly-Mascheroni, a research fellow in social and cognitive neuroscience at City St. George's University of London in the U.K., in an interview.

CTV News

3 days ago

• CTV News

More microplastics in glass bottles than plastic: study

Paris, France -- Drinks including water, soda, beer and wine sold in glass bottles contain more microplastics than those in plastic bottles, according to a surprising study released by France's food safety agency Friday. Researchers have detected the tiny, mostly invisible pieces of plastic throughout the world, from in the air we breathe to the food we eat, as well as riddled throughout human bodies. There is still no direct evidence that this preponderance of plastic is harmful to human health, but a burgeoning field of research is aiming to measure its spread. Guillaume Duflos, research director at French food safety agency ANSES, told AFP the team sought to 'investigate the quantity of microplastics in different types of drinks sold in France and examine the impact different containers can have'. The researchers found an average of around 100 microplastic particles per litre in glass bottles of soft drinks, lemonade, iced tea and beer. That was five to 50 times higher than the rate detected in plastic bottles or metal cans. 'We expected the opposite result,' PhD student Iseline Chaib, who conducted the research, told AFP. 'We then noticed that in the glass, the particles emerging from the samples were the same shape, colour and polymer composition -- so therefore the same plastic -- as the paint on the outside of the caps that seal the glass bottles,' she said. The paint on the caps also had 'tiny scratches, invisible to the naked eye, probably due to friction between the caps when there were stored,' the agency said in a statement. This could then 'release particles onto the surface of the caps', it added. Wine fine For water, both flat and sparkling, the amount of microplastic was relatively low in all cases, ranging from 4.5 particles per litre in glass bottles to 1.6 particles in plastic. Wine also contained few microplastics -- even glass bottles with caps. Duflos said the reason for this discrepancy 'remains to be explained'. Soft drinks however contained around 30 microplastics per litre, lemonade 40 and beer around 60. Because there is no reference level for a potentially toxic amount of microplastics, it was not possible to say whether these figures represent a health risk, ANSES said. But drink manufacturers could easily reduce the amount of microplastics shed by bottle caps, it added. The agency tested a cleaning method involving blowing the caps with air, then rinsing them with water and alcohol, which reduced contamination by 60 percent. The study released by ANSES was published online in the Journal of Food Composition and Analysis last month. By Rébecca Frasquet, AFP

CBC

3 days ago

• CBC

After the puzzling warmth of Earth in 2023 and 2024, what could 2025 have in store?

After 12 consecutive months with temperatures 1.5 C above the 1850-1900 average, Earth's temperature has now fallen — thanks in part to the end of a natural cycle. According to Berkeley Earth, a non-profit climate analysis organization, the global average temperature was 1.33 C above the pre-industrial average in the month of May, and the European Copernicus Climate Change Service (CCCS) found that the monthly average was 1.40 C above the pre-industrial average. (Climate agencies around the world use different methods to analyze global temperatures, hence the difference). While that may seem like good news, the fact is that 2025 is still on track to be one of the top three warmest years on record, according to Zeke Hausfather from Berkeley Earth. "With El Niño being firmly over, it is very unlikely at this point that 2025 is going to set a new record, but I still think it's the odds-on favourite to be the second-warmest on record, and it is virtually certain to be a top three warmest year," Hausfather said. El Niño, a natural, cyclical warming in a region of the Pacific Ocean that, coupled with the atmosphere, can cause global temperatures to rise, began in the middle of 2023 and then peaked in 2024, which could account for some of the record warmth that puzzled climate scientists. What was particularly interesting about the month of May is that land surface temperatures dropped quite a bit compared to the months prior. However, it was still the second warmest on record, after 2024. Hausfather said the sharp drop could have been some "internal variability" that had kept the land surface temperatures elevated and that perhaps last month was a result of the end of that variability. An important thing to also keep in mind when it comes to what we can expect in terms of 2025 making the record books, winter is when we see the greatest temperature anomalies, Hausfather said. So that could push 2025 even higher than what we're seeing now. On the road to warming trend of 1.5 C Ocean temperatures have decreased in part due the end of El Niño, but remain near record highs. In May, the average ocean temperatures were 0.99 C above the 1850-1900 average, according to Berkeley Earth. "At the moment, we are seeing, or we have just seen, a significant ocean heat wave in the North Atlantic," said Carlo Buontempo, director of Copernicus Climate Change Service (C3S). "[Ocean temperatures are] cooler than last year and the previous one, but it's warmer than any other years we have in the record. So this is one of these things where it depends [whether] we like to see the glass half full or half empty. It's still a very warm ocean." Though Earth did hit a 12-month average of 1.5 C, that doesn't necessarily mean failure on the Paris Agreement goal of keeping global warming below a threshold of 1.5 C. That would have to happen over a longer period, though there is no set timeframe set out in the agreement. Climate is looked at over long periods, typically spanning 20 or 30 years. Carbon budget running out However, a study published on Wednesday in the journal Earth System Science Data, found that — if emissions continue at 2024 rates — we have only three years until we exhaust our carbon budget to keep warming below that 1.5 C threshold. "Record-high greenhouse gas emissions are rapidly narrowing the chance of limiting warming to 1.5 C," Joeri Rogelj, professor of climate science and policy at the Centre for Environmental Policy, Imperial College London and co-author of the report, said in a statement. "The window to stay within 1.5°C is rapidly closing. Global warming is already affecting the lives of billions of people around the world." Though the that threshold may be breached, climate scientists like to stress that every tenth of a degree matters. But to keep warming below 2 C — the threshold initially set by the Paris Agreement — there needs to be a concerted effort to drastically cut CO2 emissions, as Antonio Gutteres, secretary-general of the United Nations, has continually stressed. Buontempo said that he's hopeful that the tools we have today will at least help us deal with dealing with the outcomes of rising temperatures. "I'm an optimist. I've always been an optimist, and my feeling is that, you know, there are plenty of positives in this terrible situation, including the fact that we never had so much information about our planet," Buontempo said.